Johnson & Johnson to present 26 Impella studies at TCT 2026

Johnson & Johnson MedTech will present 26 studies evaluating its Impella heart pump technology at the Transcatheter Cardiovascular Therapeutics 2026 conference in San Diego.

The programme spans high-risk percutaneous coronary intervention, cardiogenic shock, myocardial recovery, renal perfusion, physiological risk assessment and next-generation mechanical circulatory support.

The company said the presentations add to more than two decades of clinical research involving Impella.

More than 50,000 patients receiving Impella have been included in clinical studies, while over 450,000 patients worldwide have been treated with the technology.

Johnson & Johnson said the evidence base now includes around 2,700 peer-reviewed publications and has contributed to the inclusion of temporary mechanical circulatory support with Impella in 18 clinical guidelines and consensus statements.

Several studies being presented at TCT will focus on the use of Impella during high-risk percutaneous coronary intervention.

Three analyses will examine contemporary clinical experience in the U.S. and Europe and provide additional context around outcomes reported in the CHIP-BCIS3 study.

One presentation will assess real-world evidence from the TRI-GUARD-PCI registry in patients undergoing protected PCI with microaxial flow pump support.

Another analysis from the PROTECT III programme will examine early mortality in a high-risk PCI population with clinical characteristics similar to those included in CHIP-BCIS3.

The TCT programme will also include research into the potential economic impact of Impella use.

A health-economic model will compare lifetime healthcare costs and quality-adjusted survival with Impella versus intra-aortic balloon pump support in patients with heart failure undergoing high-risk PCI.

Johnson & Johnson said the analysis projects lower lifetime healthcare costs and greater quality-adjusted survival with Impella.

Additional research will examine myocardial recovery and the effects of left ventricular unloading.

An analysis from the STEMI-Door to Unload study will explore infarct size reduction associated with left ventricular unloading in patients with ST-elevation myocardial infarction.

The company will also present prospective evidence from the Impella ECP pivotal study and continuing access protocol, which are evaluating lower-profile mechanical circulatory support during high-risk PCI.

Navin Kapur, MD, Chief Medical and Scientific Officer for Heart Recovery at Johnson & Johnson MedTech, said the breadth of research reflects the company’s continued investment in generating evidence around temporary mechanical circulatory support.

He said the studies are intended to improve understanding of heart recovery and help guide clinical practice in patients with complex cardiovascular disease.

Johnson & Johnson is continuing its evidence-generation programme through several ongoing and planned studies.

These include the PROTECT IV randomised controlled trial and additional research across ischaemic heart disease, heart failure, cardiac surgery and cardiogenic shock.

The TCT 2026 conference will take place from October 31 to November 3 in San Diego.

---

---

Related Topics and Keywords

Biopharma, cardiogenic shock, cardiovascular devices, clinical research, healthcare economics, heart failure, heart pumps, high-risk PCI, HRPCI, Impella, Impella ECP, interventional cardiology, Johnson and Johnson, Johnson and Johnson MedTech, left ventricular unloading, mechanical circulatory support, medtech, myocardial recovery, pharma news, PROTECT III, PROTECT IV, STEMI-Door to Unload, TCT 2026, TRI-GUARD-PCI